Immunotherapy Coverage from Every Angle


CXCR1/2 Inhibitor Plus Pembrolizumab in Metastatic Melanoma: Early-Phase Trial Results
Easing the Effects of T-DXd: Electronic Symptom Tracking Tested in PRO-DUCE Trial
Neoadjuvant Immunotherapy for Squamous Cell Skin Cancer
Lifileucel Plus Pembrolizumab Active in Melanoma Setting in Phase II Trial
Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC
Novel Monoclonal Antibody and Chemotherapy Under Study in Nonmelanoma Skin Cancer
Vaccine Plus Immunotherapies Under Investigation in Advanced Melanoma
Comparing Therapies for Transplant-Ineligible Patients Newly Diagnosed With Myeloma
Palbociclib-Based Therapy for HER2-Positive and PAM50 Luminal Advanced Breast Cancer
mRNA Vaccine Under Study in Merkel Cell Carcinoma
Antibody-Drug Conjugate ARX788 Under Study in HER2-Positive Breast Cancer
Advanced Cutaneous Squamous Cell Carcinoma: Predicting Response to Immune Checkpoint Inhibitor Therapy
$600K Grant Awarded to Wistar Researcher to Study Impact of Microbial Genes on Immunotherapy Response in Melanoma
Amivantamab Plus Lazertinib in High-Risk Subgroups With Advanced NSCLC
ASCO 2024: Targeted Triplet for Leptomeningeal Metastasis in HER2-Positive Breast Cancer
Neoadjuvant Use of Pembrolizumab in Locally Advanced Squamous Cell Skin Cancer
ASCO 2024: Study Analysis Focuses on Nodal Status With Neoadjuvant Nivolumab in Stage III NSCLC
ASCO 2024: Impact of Discontinuing Immunotherapy After Response in Merkel Cell Carcinoma
ASCO 2024: Phase I Findings on Novel Bispecific Protein for Cutaneous Melanoma
ASCO 2024: Quadruplet vs Triplet Regimen for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
ASCO 2024: Triplet Regimen Under Study in High-Risk, Resectable Melanoma
ASCO 2024: DREAMM-7 Subgroup Analyses Support BVd in Resistant Myeloma
ASCO 2024: New Antibody-Drug Conjugate Under Study in First Line for Advanced NSCLC
ASCO 2024: Adjuvant Use of Avelumab in High Risk, Early-Stage Triple-Negative Breast Cancer
ASCO 2024: KEYNOTE-942 Evaluates mRNA-4157 Plus Pembrolizumab in Resected Melanoma
ASCO 2024: Quality of Life With Neoadjuvant Immunotherapy for Stage III Melanoma
ASCO 2024: MUC1 Vaccine Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
ASCO 2024: Use of Tilsotolimod Plus Ipilimumab vs Ipilimumab Alone in Advanced Melanoma
ASCO 2024: Can Idecabtagene Vicleucel Improve Outcomes in Extramedullary Multiple Myeloma?
ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC
ASCO 2024: Immunotherapy for Ulcer-Related Squamous Cell Skin Cancer
ASCO 2024: Results From EV-202 of Enfortumab Vedotin in Breast Cancer Cohorts
ASCO 2024: BRAF and MEK Inhibitors Plus Immunotherapy for BRAF V600E/K–Mutated Melanoma
ASCO 2024: Taxane-Free First-Line Regimen for Advanced HER2-Positive Breast Cancer
ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC
ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC
ASCO 2024: Risk-Adapted Surgical De-escalation for Resectable Squamous Cell Carcinoma
ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer
ASCO 2024: Triplet Immunotherapy Regimen Focus of Study in Advanced Melanoma
ASCO 2024: Is Belantamab Mafodotin Making a Comeback in the DREAMM-8 Myeloma Trial?
ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer
ASCO 2024: Phase III Trial Evaluates Neoadjuvant Immunotherapy for Stage III Melanoma
Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy for Resectable NSCLC
STK11 Mutations and Immunotherapeutic Efficacy in NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.